ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Completed · Phase 2/Phase 3

Conditions studied: Dry Eye

In brief

Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease

Key facts

Study ID

NCT04899518

Run by

Allysta Pharmaceutical

People needed

922

Starts

2021-05-19

Expected to finish

2023-03-14

Last updated by the study team

2023-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Dry eye disease for > 3 months meeting specific sign and symptom criteria
• Best corrected visual acuity of +0.6 logMAR or better
• Willing to sign informed consent and attend study visits
• Willing to comply with contraception requirements

You may not qualify if…

• Unable to meet specific sign and symptom criteria
• Signs of ophthalmic allergic, inflammatory or infection conditions
• Use of contact lenses
• Anatomic abnormalities preventing accurate study assessments
• Use of medications that influence eye dryness
• Recent ophthalmic surgery
• Unwilling to suspend current treatments for dry eye disease

Where it is running

• Allysta Pharmaceuticals — Bellevue, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.